Featured
MA Board voting opens: three leaders, two seats
Voting opens today to fill vacancies on the Medicines Australia board with three leaders putting their hand up for two positions
Featured
New office brings pharma team together
A change of headquarters to a brand new office space is planned to increase collaboration between teams
Industry & Companies
Shares skyrocket 30% on new trial data
In one of the most competitive markets in the world, this company is looking to reinvent the space, and its latest topline trial results have impressed
Industry & Companies
Pharma downsizes in Australia
This company is downsizing its office space following the latest restructuring in Australia, with an official move slated for the start of next month
Industry & Companies
Aussie staff let go as pharma put up for sale
A Sydney-based pharma is up for sale, with almost the entire workforce wiped out, following the appointment of a Voluntary Administrator
Industry & Companies
Psychedelic medicines flying high
Three years after Australia's world-first decision to permit the prescribing of psilocybin and MDMA, the sector is booming and Big Pharma's are making a play
Leadership & People
Global genomics boss heading to Australia
The Chief Scientific Officer for the NHS will visit Australia next month with a packed schedule including an address to the National Press Club
Regulation & Legal
Speed bump ahead for NZ fast-track?
New approvals pathway could put the country at risk of contravening an international trade agreement, according to lawyers
Featured
Changed global pricing environment sinks PBS listing
The shortest line yet between America's MFN policy and a life-saving drug not being PBS listed has been drawn, with a company decrying the PBAC's unwillingness to adapt to a changed pricing environment
Featured
Lilly goes direct for non-PBS meds
Faced with growing challenges to listing some drugs on the PBS, Lilly has launched a platform to facilitate dispensing and delivery of medications to a patient's door at more affordable prices
Regulatory & Reimbursement
Drug slated for PBS delisting gets more time
While manufacturing costs have gone up, reimbursement is less than half what it was when this drug was first listed but the PBAC still said 'No' to a price rise. Now plans to delist it from the PBS have been delayed by six months following a patient outcry
Jobs & Workplace
115 years on: First female CEO appointed
This member-led organisation has appointed the first female CEO in its 115-year history, following a national recruitment drive
Regulatory & Reimbursement
Nine pharmas seek to add new drug labels
Nine pharmas hope to add new labels to their drugs in Australia in 2027 after the TGA accepted their applications for evaluation between June and July
Jobs
Regulatory & Reimbursement
10 innovative drugs land on TGA review desk
Australia's medicines regulator has accepted an additional 10 Type A applications between June and July, with some pegged blockbusters making the list
Latest
And again... Keytruda challenger shapes up
Another impressive trial win for Summit Therapeutics' challenger to the world's biggest drug has been branded a good omen for Big Pharmas in the same space
Industry & Companies
Novo unveils five multi-blockbuster plan
Company details future mega revenue earners while also releasing topline results for its next star performer, which beat a rival Lilly drug in a head-to-head trial
Featured
Senior leadership shake-up sweeps industry
There has a been a rush on senior leadership moves across industry with a string of departures, returns, company moves and internal promotions
Regulatory & Reimbursement
Chilling forecast on future PBS spending
The Federal Government's Intergenerational Report forecasts PBS spending will grow more slowly than health spending as a whole
Regulatory & Reimbursement
Copycats hit PBS bottleneck
Biosimilar and generic drugmakers have emerged as the top contenders to secure an October PBS listing, including one drug that could force a price cut for a $72 million-a-year blockbuster
Industry & Companies
Telix pays $3.3B to lock up the market
The local giant has shored up isotope supply for its late-stage pipeline with the icing on the cake, acquiring a radiopharmaceutical on the cusp of winning FDA approval
Latest
Novo dragged into horror DV weekend
Media reports of a spate of domestic violence homicides over the weekend included one accused's defence that he was affected by Ozempic.
Regulatory & Reimbursement
Early October listings climb to four
Health Minister Mark Butler announces another two October listings, one of which will benefit more than 143,000 Australians from the start of next month
Regulatory & Reimbursement
Novel therapy heading to Australia
Under an expanded deal, this company has snagged Australian rights to a new topical formulation of a well-known JAK inhibitor
Regulatory & Reimbursement
TGA approves new flu jab
A new vaccine has been approved by the TGA for adults along with new versions of drugs sponsored by Celltrion Healthcare, Kyowa Kirin, and UCB.
- Jobs & Workplace Another Aussie CEO departs for 'personal reasons'
- Regulation & Legal New law gives patients driving exemption
- Regulatory & Reimbursement Policy 'earthquake' reshaping pharma
- Jobs & Workplace Ex-pharma leader joins fast-growing agency
- Regulatory & Reimbursement PBAC to PBS: the fastest-moving submissions
- Regulatory & Reimbursement Another October listing as Govt rushes to beat deadline
- Industry & Companies Australia a key market for new platform
- Leadership & People Who's given Mark Butler an award?
- Industry & Companies Amgen releases roadmap for post-cardiac care
- Industry & Companies Pharma skyrockets up World's Best Companies list
